Department of Ophthalmology, Landspitali-The National University Hospital of Iceland, Reykjavik, Iceland.
Br J Ophthalmol. 2012 Mar;96(3):444-7. doi: 10.1136/bjophthalmol-2011-300304. Epub 2011 Aug 19.
BACKGROUND/AIMS: The use of intravitreal vascular endothelial growth factor antibodies for exudative age-related macular degeneration (AMD) has stressed ophthalmology services and drug budgets throughout the world. The authors study the population-based incidence of exudative AMD in Iceland and the use of intravitreal ranibizumab in a defined population.
This is a prospective study of 439 consecutive patients aged 60 years and older with exudative AMD starting intravitreal ranibizumab for exudative AMD in Iceland from March 2007 to December 2009. All patients initially received three consecutive ranibizumab injections, with regular follow-up visits and re-treatment as needed.
In total, 517 eyes from 439 patients received treatment for exudative AMD (mean age 79 years). The annual incidence of exudative AMD in the population 60 years and older is 0.29%. The incidence increased with advancing age, double for patients 85 years and older compared with those 75-79 years. Approximately 2400 ranibizumab injections per 100,000 persons aged 60 years and older were given each year for exudative AMD.
These data allow an estimation of the incidence of exudative AMD in a Caucasian population and the treatment load with ranibizumab, which may help plan anti-vascular endothelial growth factor treatment programmes and estimate costs.
背景/目的：玻璃体内血管内皮生长因子抗体的应用已对全球眼科服务和药物预算造成了压力，尤其是用于治疗渗出型年龄相关性黄斑变性（AMD）。作者研究了冰岛渗出型 AMD 的人群发病率以及在特定人群中应用玻璃体内雷珠单抗的情况。
这是一项对 2007 年 3 月至 2009 年 12 月冰岛开始应用玻璃体内雷珠单抗治疗渗出型 AMD 的 439 例连续渗出型 AMD 患者的前瞻性研究。所有患者最初均接受连续 3 次雷珠单抗注射，随后定期进行随访，并根据需要进行再次治疗。
共有 439 例患者的 517 只眼接受了渗出型 AMD 的治疗（平均年龄 79 岁）。60 岁及以上人群中渗出型 AMD 的年发病率为 0.29%。发病率随年龄增长而增加，85 岁及以上患者是 75-79 岁患者的两倍。每年每 10 万 60 岁及以上人群中约有 2400 次玻璃体内雷珠单抗注射用于渗出型 AMD 的治疗。
这些数据可以估计白种人群中渗出型 AMD 的发病率以及雷珠单抗的治疗负担，这有助于制定抗血管内皮生长因子治疗方案并估计成本。
